Well, the stock is up only 7%. Will see if the presentation in Boston will be of some help. <g>
Introgen Presents Top Line Data from Phase III ADVEXIN(R) Clinical Trial
Thursday May 29, 9:06 am ET
AUSTIN, Texas--(BUSINESS WIRE)--Study results from Introgen Therapeutics, Inc.’s (NASDAQ:INGN - News) phase III ADVEXIN® (p53 tumor suppressor therapy) clinical trial will be presented as a late-breaking, oral presentation today at the American Society for Gene Therapy (ASGT) annual meeting in Boston, Mass.
To access the ASGT presentation on Introgen’s web site please visit the Events page at www.introgen.com; the presentation will be posted at approximately 11:00 am. E.T. The results demonstrate that ADVEXIN has significantly increased survival in end-stage head and neck cancer patients.
Data will be presented by study principal investigator, John Nemunaitis, MD, medical director, Mary Crowley Cancer Research Centers at Baylor-Charles A. Sammons Cancer Center in Dallas, TX.
The presentation and ADVEXIN therapy was also described in a news release from M.D. Anderson Cancer Center
mdanderson.org -82BB-4FCB-9FAB5CF9FA51DEFF&method=displayFull&pn=00c8a30f-c468-11d4-8 0fb00508b603a14.
(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
Jack A. Roth, MD, Professor and Bud Johnson Clinical Distinguished Chair, Department of Thoracic & Cardiovascular Surgery, Section Chief, Thoracic Molecular Oncology, and Director, W.M. Keck Cancer Center for Innovative Cancer Therapies, M.D. Anderson Cancer Center, Houston, TX will be recognized for his contributions as the inventor of ADVEXIN. Drs. Nemunaitis and Roth will answer questions at the conclusion of the presentation.
Snip
Bernard |
